www.rttnews.com ·
sellas life sciences posts wider q1 loss nears pivotal aml trial readout stock up
Topic context
This topic has been covered 349669 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedSELLAS Life Sciences is a clinical-stage biotech. The increased loss is due to higher R&D costs for its pivotal AML trial. The stock price rise reflects anticipation of trial readout. No direct commercial mechanism beyond the company's own pipeline progress; no supply chain or pricing impact on other products.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 net loss $8.4M vs $5.8M in Q1 2025
- Phase 3 REGAL trial in AML nearing final analysis (78/80 events)
- SLS009 Phase 2 study in newly diagnosed AML underway (80 patients)
- Cash and equivalents $107.1M at quarter end
- Stock closed at $5.22, overnight trading $6.09
SELLAS stock expected to remain flat in the mid-term; 0-5% change anticipated over 1-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort